Amendment to 3rd-Party Allotment Capital Increase
에이프릴바이오
397030
Signal Score
Historical Avg Return (5d)
+0.00%
Data Coverage
100%n=2604
Risk-adjusted indicator based on 2604 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEGATIVE
Key Numbers
- • Allotted Shares (IMM Healthcare No. 8 Limited Company): 1,100,029 Shares
- • Allotted Shares (IMM Scale-up Bio No. 1 Limited Company): 122,225 Shares
- • Initial Conversion Price: 40,908 KRW per share
- • Minimum Preferred Dividend Rate: 1% of par value per annum
AI Analysis Summary
AprilBio Co.,Ltd. filed an amendment to its Material Fact Report regarding a paid-in capital increase via third-party allotment. The amendment primarily changes the third-party allottee from IMM Asset Management Co., Ltd. to IMM Healthcare No. 8 Limited Company, a special purpose company (SPC) established by IMM Healthcare No. 8 Private Equity Fund. A total of 1,100,029 shares will be allotted to IMM Healthcare No. 8 Limited Company and 122,225 shares to IMM Scale-up Bio No. 1 Limited Company, with all shares subject to a one-year lock-up period. The new shares are participating, cumulative preferred shares with a minimum annual dividend rate of 1% of par value and an initial conversion price of 40,908 KRW per share. This capital increase is for operational funds, but the change in allottee to an SPC and the issuance of convertible preferred shares could lead to future dilution for existing shareholders.
How This Event Is Evaluated
Capital Raise Evaluation
Capital raise events are evaluated by estimating dilution pressure, funding purpose, pricing terms, and impact on existing shareholders.
AI is used to interpret disclosures and extract structured data.
Signal scores are generated using event-specific methodologies and quantitative models.
- Potential dilution rate
- Issuance or conversion price
- Funding purpose
- Shareholder value impact
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.